Literature DB >> 12625919

Progress towards, and challenges for, the elimination of filariasis from Pacific-island communities.

T R Burkot1, G Taleo, V Toeaso, K Ichimori.   

Abstract

The Pacific Programme for the Elimination of Lymphatic Filariasis (PacELF) - the first regional campaign to attempt to eliminate filariasis as a public-health problem - is using five, annual, mass drug administrations (MDA) of diethylcarbamazine (DEC) plus albendazole to stop transmission. In 2001, nine countries and territories covered by the programme had begun annual MDA campaigns, with population treatment coverages ranging from 52% to 95%. By the end of 2002, it is anticipated that 11 countries/territories will have begun such MDA campaigns. Even with high MDA coverage, the efficiency of Aedes polynesiensis as a vector of Wuchereria bancrofti may limit the effectiveness of the elimination campaigns in some countries. In areas of limited MDA coverage, additional strategies, such as vector control (as a adjunct to the MDA), or alternative approaches, such as the use of DEC-fortified salt, may be necessary to stop transmission.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12625919     DOI: 10.1179/000349802125002419

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN: 0003-4983


  11 in total

1.  Epidemiological assessment of continuing transmission of lymphatic filariasis in Samoa.

Authors:  H Joseph; F Maiava; T Naseri; U Silva; P Lammie; W Melrose
Journal:  Ann Trop Med Parasitol       Date:  2011-12

2.  Monitoring temporal abundance and spatial distribution of Aedes polynesiensis using BG-Sentinel traps in neighboring habitats on Raiatea, Society Archipelago, French Polynesia.

Authors:  David R Mercer; Herve Bossin; Michel Cheong Sang; Linda O'Connor; Stephen L Dobson
Journal:  J Med Entomol       Date:  2012-01       Impact factor: 2.278

Review 3.  Are coinfections of malaria and filariasis of any epidemiological significance?

Authors:  Ephantus J Muturi; Benjamin G Jacob; Chang-Hyun Kim; Charles M Mbogo; Robert J Novak
Journal:  Parasitol Res       Date:  2007-11-20       Impact factor: 2.289

4.  Immune activation by life-shortening Wolbachia and reduced filarial competence in mosquitoes.

Authors:  Zakaria Kambris; Peter E Cook; Hoang K Phuc; Steven P Sinkins
Journal:  Science       Date:  2009-10-02       Impact factor: 47.728

5.  Male mating competitiveness of a Wolbachia-introgressed Aedes polynesiensis strain under semi-field conditions.

Authors:  Eric W Chambers; Limb Hapairai; Bethany A Peel; Hervé Bossin; Stephen L Dobson
Journal:  PLoS Negl Trop Dis       Date:  2011-08-02

6.  Application of the Filariasis CELISA Antifilarial IgG(4) Antibody Assay in Surveillance in Lymphatic Filariasis Elimination Programmes in the South Pacific.

Authors:  Hayley Joseph; Fuatai Maiava; Take Naseri; Fasihah Taleo; Malakai 'ake; Corinne Capuano; Wayne Melrose
Journal:  J Trop Med       Date:  2011-09-26

7.  Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis.

Authors:  Cara L Macfarlane; Shyam S Budhathoki; Samuel Johnson; Marty Richardson; Paul Garner
Journal:  Cochrane Database Syst Rev       Date:  2019-01-08

8.  The argument for integrating vector control with multiple drug administration campaigns to ensure elimination of lymphatic filariasis.

Authors:  T R Burkot; D N Durrheim; W D Melrose; R Speare; K Ichimori
Journal:  Filaria J       Date:  2006-08-16

Review 9.  A critical assessment of vector control for dengue prevention.

Authors:  Nicole L Achee; Fred Gould; T Alex Perkins; Robert C Reiner; Amy C Morrison; Scott A Ritchie; Duane J Gubler; Remy Teyssou; Thomas W Scott
Journal:  PLoS Negl Trop Dis       Date:  2015-05-07

10.  Molecular xenomonitoring using mosquitoes to map lymphatic filariasis after mass drug administration in American Samoa.

Authors:  Mark A Schmaedick; Amanda L Koppel; Nils Pilotte; Melissa Torres; Steven A Williams; Stephen L Dobson; Patrick J Lammie; Kimberly Y Won
Journal:  PLoS Negl Trop Dis       Date:  2014-08-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.